Supplier News Breaks Archives
Actavis restructures specialty sales organization
November 20th, 2013
DUBLIN, Ireland – Actavis plc announced that it has completed the restructuring of its U.S. Specialty Brands sales organization in the wake of its acquisition of Warner Chilcott.
Actavis said Wednesday that Actavis Specialty Brands will have a sales organization of about 750 U.S. sales professionals, including sales representatives, district managers, national account managers and associated management, compared with a combined total of approximately 1,100 legacy Actavis and legacy Warner Chilcott sales professionals as of the close of the acquisition on Oct. 1.
The restructured sales organization will have equal or better coverage than the legacy Warner Chilcott sales organization in all therapeutic areas, including women's health, urology, gastroenterology and dermatology, Actavis noted. The revamped organization also includes a number of institutional representatives to support promotion to clinics.
"Beginning at close, we initiated an extensive assessment and review process to determine the appropriate structure for our U.S. Specialty Brands sales organization, recognizing that the two companies had significant overlap in key areas," stated Fred Wilkinson president of Actavis Specialty Brands. "I am confident that this organization will be an industry leader in providing support to healthcare professionals within the women's health, urology, dermatology and GI therapeutic categories."
He added, "We are committed to supporting those professionals who were not selected as a result of this review process with appropriate severance benefits and support including outplacement services. We anticipate a smooth transition to this new sales organization and to seamlessly supporting our physician base."
The company said it expects to outline the complete structure of the new Specialty Brands commercial organization at its investor day in January.
Early last month, Actavis formed a new board of directors with the completion of the Warner Chilcott acquisition. With the $8.5 billion deal, the drug makers have combined under a new company incorporated in Ireland. The merged company has adopted the global name Actavis plc.